Polyceutix - About the company
Polyceutix is a funded company based in Copenhagen (Denmark), founded in 2023. It operates as a Developer of immunomodulatory compounds for treating muscle invasive bladder cancer. The company has 14 active competitors, including 2 funded and 5 that have exited. Its top competitors include companies like UroGen Pharma, Lipella and Protara Therapeutics.
Company Details
Developer of immunomodulatory compounds for treating muscle invasive bladder cancer. This technology involves a copolymer injected into tumors to solubilize lipid bilayers and membrane proteins. The resulting particles release cancer neoantigens, which are taken up by immune cells to trigger an adaptive anti-tumor response. An attached agonist further amplifies this immune activation to produce a therapeutic effect within the tumor.
Key Metrics
Founded Year
2023
Location
Copenhagen, Denmark
Stage
Funding Raised
Investors
Ranked
18th among 18 competitors
Similar Companies
Sign up to download Polyceutix's company profile
Polyceutix's funding and investors
Polyceutix is a funded company. Polyceutix has 1 institutional investor.
View details of Polyceutix's funding rounds and investors
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Polyceutix's Competitors and alternates
Top competitors of Polyceutix include UroGen Pharma, Lipella and Protara Therapeutics. Here is the list of Top 10 competitors of Polyceutix, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | UroGen Pharma 2004, Ra anana (Israel), Public | Developer of therapeutics to treat urothelial and specialty cancers | $7M | 64/100 | |
2nd | Lipella 2005, Pittsburgh (United States), Public | Developer of lipid-based therapies for common bladder syndromes | $3.37M | 57/100 | |
3rd |  Protara Therapeutics 2017, New York City (United States), Public | Developer of cell therapies to treat lymphatic malfunctions | - | 52/100 | |
4th |  Prokarium 2012, London (United Kingdom), Series C | Developer of bacterial immunotherapy treatments for various types of cancer | $70M | 52/100 | |
5th | Relmada 2007, Blue Bell (United States), Public | Developing innovative therapies for debilitating disorders, improving human health | $13M | 51/100 | |
6th |  Asieris Pharmaceuticals 2010, Radnor (United States), Unfunded | Developer of drugs for the treatment of genitourinary tumors and other major diseases | - | - | 50/100 |
7th | Developer of drugs for treating cancer | $6.97M | 38/100 | ||
8th |  Rainer Theraputics 2010, San Leandro (United States), Deadpooled | Developer of antibody based therapeutics for bladder cancer | $156M | 35/100 | |
9th | Tengion 2004, Audubon (United States), Deadpooled | Regenerative medicine company developing neo-organs & neo-tissues. | $143M | 35/100 | |
10th |  OncoSTING 2018, Baltimore (United States), Funding Raised | Developer of immunotherapy for bladder cancer | - | 32/100 | |
18th |  Polyceutix 2023, Copenhagen (Denmark), Funding Raised | Developer of immunomodulatory compounds for treating muscle invasive bladder cancer | - | 15/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Polyceutix's competitors? Click here to see the top ones
Polyceutix's Investments and acquisitions
Polyceutix has made no investments or acquisitions yet.
Are you a Founder ?
FAQs about Polyceutix
Explore our recently published companies
- Beauty Tech Co - Kuwait based, Public company
- Twiga CG - Russia based, 1993 founded, Public company
- Edify - San Francisco based, 2025 founded, Public company
- TongueTek - West Grove based, Public company
- MENTZ - Germany based, 1972 founded, Public company
- Design Engineering - Metairie based, 1984 founded, Public company
